EE55 Cost-Effectiveness of ESMO-Recommended Lenvatinib and Pembrolizumab Regimen as Second-Line Treatment for Advanced Endometrial Carcinoma in Taiwan: A Comparison With NCCN Recommendations

Saved in:

Bibliographic Details
Published in	Value in health Vol. 26; no. 12; p. S60
Main Authors	Chueh, C.H., Ho, P.K., Chiang, S.T., Wen, Y.W., M.N., Shiu, Liu, J.H., Li, W.H., Tsai, Y.W.
Format	Journal Article
Language	English
Published	01.12.2023
Online Access	Get full text

Loading…

More Information
ISSN:	1098-3015
DOI:	10.1016/j.jval.2023.09.328